雷贝拉唑三联治疗幽门螺杆菌相关性消化性溃疡疗效观察

Efficacy of rabeprazole based triple therapy in the treatment of helicobacter pylori-related peptic ulcer

目的观察雷贝拉唑联用呋喃唑酮、克拉霉素治疗幽门螺杆菌(Hp)相关性消化性溃疡的疗效。方法胃镜检查确认消化性溃疡且13C尿素呼气试验Hp阳性的86例患者,随机分为治疗组(A组)和对照组(B组)各43例;A组口服雷贝拉唑、呋喃唑酮、克拉霉素治疗,B组将A组方案中的雷贝拉唑替换为奥美拉唑。结果两组治疗7 d后症状改善率分别为97.67%和88.38%,Hp根治率分别为90.70%和67.44%,两组在症状改善率和Hp根治率上差异有统计学意义(P<0.05)。结论雷贝拉唑三联治疗Hp相关性消化性溃疡在缓解症状、根除Hp较其他方案有更佳的效价比。

Objective To observe the efficacy of rabeprazole, furazolidone and clarithromycin based triple therapy in the treatment of helicobacter pylori-related peptic ulcer. Methods Eighty-six patients with peptic ulcer and Hp infection by endoscopic examination and urea breath test were randomized to treatment group （group A） and control group （group B） with 43 cases in each. Group A took orally rabeprazole, furazolidone and clarithromycin; Group B changed rabeprazole of group A to omeprazole, and others medicine had no change. Results Symptomatic relief was found 97.67% and 88.38% in two groups after 7 days, Hp eradication rate was 90.70% and 67.44%; Symptomatic relief rate and Hp eradication rate of two groups were significantly different （P〈0.05）. Conclusion Rabeprazole, furazolidone and clarithromycin based triple therapy in the treatment of helicobacter pylori-related peptic ulcer has good efficacy and low cost.